New ovarian cancer test developed
26 September, 2002 by Claire DobleAn improved test for ovarian cancer has been developed by Melbourne researchers. The team from Prince Henry's Institute of Medical Research and Monash University's Department of Obstetrics and Gynaecology has developed a test that, in conjunction with the standard test, can detect 90-95 per cent of cancers.
Melbourne Uni teams up with US company for Alzheimer's drugs
26 September, 2002 by Melissa TrudingerLooking to develop new methods to test Alzhiemer's drugs, US-based company Axonyx has signed an agreement with University of Melbourne's Dr David Small.
Melbourne researchers uncover new diabetes syndrome
26 September, 2002 by Graeme O'NeillA Melbourne University study has thrown new light on a dangerous complication of insulin-dependent diabetes called hypoglycaemic unawareness, which can cause diabetics to lapse into an insulin-induced coma.
Virus find reinforces Biotron's 'exit strategy'
24 September, 2002 by Graeme O'NeillDirectors of Canberra-based HIV drug-therapeutic company Biotron have announced that the company's researchers have confirmed that two Australian native viruses -- Ross River Virus, the agent of epidemic polyarthritis, and its cousin, Barmah Forest Virus -- possess genes for ion channels.
Researchers get clear picture of cancer growth factor
20 September, 2002 by Graeme O'NeillThe crystal ball has cleared, and a Melbourne research team has seen one of the shapes of the future in cancer research, after solving the elusive structure of a receptor for a growth factor involved in many common cancers.
Researchers assessing AustCancer Phase II vaccine trial
19 September, 2002 by Graeme O'NeillPerth-based cancer therapeutics company Australian Cancer Technology announced today that researchers at St Vincent's Hospital, Sydney have begun analysing results from the first group of patients in its Phase Ib/IIa clinical trial of its Pentrix vaccine for common cancers.
Two-for-one gastric research result - plus a bonus
13 September, 2002 by Graeme O'NeillTake one gene, introduce two different mutations, and reproduce the symptoms of two major diseases of the digestive tract: gastric cancer and inflammatory bowel disease. And in addition to that two-for-one result, Assoc Prof Andy Giraud of Melbourne University (Western Hospital) and Dr Matthias Ernst of the Ludwig Institute for Cancer Research have convicted a suspect gene that their US and Japanese peers had previously exonerated.
Panbio finds R&D leader in its own backyard
05 September, 2002 by Pete YoungMedical diagnostics company Panbio has headhunted Prof Stuart Hazell, dean of the University of Southern Queensland's science faculty, as its vice-president for R&D.
Griffith, Monash researchers behind new start-up
04 September, 2002 by Pete YoungTwo leading Australian scientists - Prof Mark von Itzstein and Prof Ross Coppel - have helped form a new company to deliver novel pharmaceuticals for use against drug-resistant bacteria.
Monash IRD creates mouse model for neuro disease
04 September, 2002 by Melissa TrudingerResearchers at the Monash Institute of Reproduction and Development have succeeded in creating a transgenic mouse model for Kennedy disease, a neurodegenerative disease that affects approximately 1 in 50,000 men.
Autogen presents diabetes findings at Brazil conference
29 August, 2002 by Melissa TrudingerThe discovery of a gene that links type 2 diabetes and heart disease could lead to the development of new therapeutic treatments for diabetes, according to Victorian biotech Autogen.
Good results boost AustCancer breast cancer program
28 August, 2002 by Melissa TrudingerWA-headquartered Australian Cancer Technology has accelerated its breast cancer therapeutic program after reporting good first-stage results.
$118m for institutes in NHMRC program grants
28 August, 2002 by Melissa TrudingerSixteen National Health and Medical Research Council program grants worth more than $118 million have been awarded to research teams at some of Australia's top research institutions.
Metabolic nets BIF grant for pre-clinical studies
23 August, 2002 by Melissa TrudingerMelbourne company Metabolic Pharmaceuticals has received a BIF grant of $234,700 to pursue pre-clinical studies on an orally available iron-chelating compound.
Malaria vaccine breakthrough for WEHI
15 August, 2002 by Melissa TrudingerGroundbreaking research on a malaria toxin could lead to the development of an effective vaccine for the deadly disease according to a paper published in the August 15 issue of Nature.
